TUI AG

  • WKN: TUAG00
  • ISIN: DE000TUAG000
  • Land: Germany

Nachricht vom 13.10.2021 | 15:40

TUI AG: NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

TUI AG (TUI)
13-Oct-2021 / 15:40 CET/CEST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

David Burling

2

Reason for the notification

a)

Position/status

Member of the Executive Board

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

TUI AG

b)

LEI

529900SL2WSPV293B552

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

 

Subscription Rights, settled in the form of depositary interests ("DI Pre-emptive Rights") granted pursuant to the capital increase rights issue.

 

ISIN: DE000TUAG1D6

b)

Nature of the transaction

 

 

Booking of DI Pre-Emptive Rights into account, pursuant to the capital increase rights issue.

c)

Price(s) and volume(s)

 

 

 

 

Price(s)

Volume(s)

0.00 EUR

 14452 DI Pre-emptive Rights

 

d)

Aggregated information

-         Aggregated volume

-         Price

As above.

e)

Date of the transaction

2021-10-12

 

f)

Place of the transaction

Outside a trading venue

 

 




show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021